Mobia Medical (MOBI) Q2 FY26 earnings call

Mobia Medical reported strong Q2 FY26 results, driven by significant revenue growth and expansion of its Vivistim therapy for chronic stroke survivors. The company successfully completed its IPO, strengthening its balance sheet to accelerate commercialization and geographic expansion. While net losses increased due to investment in growth and IPO-related costs, management expressed confidence in its predictable commercial model and the long-term market opportunity.